ADPT

SEC source: 0001209191-20-045397 · doc4.xml · nonDerivative · entry 4

BENZENO SHARON · CIK 0001780854 · Chief Business Development Off

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,187

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 16, 2020.

SEC source: 0001209191-20-045397 · doc4.xml · nonDerivative · entry 3

BENZENO SHARON · CIK 0001780854 · Chief Business Development Off

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,770

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 16, 2020.

SEC source: 0001209191-20-045397 · doc4.xml · nonDerivative · entry 2

BENZENO SHARON · CIK 0001780854 · Chief Business Development Off

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,208

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 16, 2020.

SEC source: 0001209191-20-045397 · doc4.xml · nonDerivative · entry 1

BENZENO SHARON · CIK 0001780854 · Chief Business Development Off

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,604

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 16, 2020.

SEC source: 0001209191-20-045396 · doc4.xml · derivative · entry 6

HILL NANCY LOUISE · CIK 0001780790 · EVP, Operations & Program Mana

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 99,000

Underlying: Common Stock · 1,600 shares

Expires 2023-11-03

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 21, 2020.

F3 · derivative.exercise_date: The option is fully vested and exercisable.

SEC source: 0001209191-20-045396 · doc4.xml · nonDerivative · entry 2

HILL NANCY LOUISE · CIK 0001780790 · EVP, Operations & Program Mana

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,000

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 21, 2020.

SEC source: 0001209191-20-045396 · doc4.xml · nonDerivative · entry 1

HILL NANCY LOUISE · CIK 0001780790 · EVP, Operations & Program Mana

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,600

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 21, 2020.

SEC source: 0001209191-20-044370 · doc4.xml · derivative · entry 11

ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 294,720

Underlying: Common Stock · 16,680 shares

Expires 2021-12-20

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019.

F7 · derivative.exercise_date: The options are fully vested and exercisable.

SEC source: 0001209191-20-044370 · doc4.xml · nonDerivative · entry 8

ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,778,180

F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019.

F6 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $37.70 to 37.89, inclusive.

SEC source: 0001209191-20-044370 · doc4.xml · nonDerivative · entry 7

ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,779,380

F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019.

F5 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $36.74 to 37.51, inclusive.

SEC source: 0001209191-20-044370 · doc4.xml · nonDerivative · entry 6

ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,794,860

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019.

SEC source: 0001209191-20-044370 · doc4.xml · derivative · entry 10

ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 311,400

Underlying: Common Stock · 16,680 shares

Expires 2021-12-20

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019.

F7 · derivative.exercise_date: The options are fully vested and exercisable.

SEC source: 0001209191-20-044370 · doc4.xml · nonDerivative · entry 5

ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,778,180

F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019.

F4 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $37.86 to 38.12, inclusive.

SEC source: 0001209191-20-044370 · doc4.xml · nonDerivative · entry 4

ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,788,064

F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019.

F3 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $36.86 to 37.85, inclusive.

SEC source: 0001209191-20-044370 · doc4.xml · nonDerivative · entry 3

ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,794,860

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019.

SEC source: 0001209191-20-044370 · doc4.xml · derivative · entry 9

ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 328,080

Underlying: Common Stock · 20,668 shares

Expires 2021-12-20

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019.

F7 · derivative.exercise_date: The options are fully vested and exercisable.

SEC source: 0001209191-20-044370 · doc4.xml · nonDerivative · entry 2

ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,778,180

F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019.

F2 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $37.58 to 38.53, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

SEC source: 0001209191-20-044370 · doc4.xml · nonDerivative · entry 1

ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,798,848

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019.

SEC source: 0001209191-20-043678 · doc4.xml · derivative · entry 5

Taylor Stacy L · CIK 0001799081 · SVP and General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 35,417

Underlying: Common Stock · 1,771 shares

Expires 2028-04-24

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019.

F4 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on March 12, 2019, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.

SEC source: 0001209191-20-043678 · doc4.xml · derivative · entry 4

Taylor Stacy L · CIK 0001799081 · SVP and General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 38,363

Underlying: Common Stock · 1,109 shares

Expires 2029-04-23

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019.

F3 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on April 23, 2020, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.

SEC source: 0001209191-20-043678 · doc4.xml · nonDerivative · entry 3

Taylor Stacy L · CIK 0001799081 · SVP and General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,300

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019.

F2 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $35.83 to 36.40, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

SEC source: 0001209191-20-043678 · doc4.xml · nonDerivative · entry 2

Taylor Stacy L · CIK 0001799081 · SVP and General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,180

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019.

SEC source: 0001209191-20-043678 · doc4.xml · nonDerivative · entry 1

Taylor Stacy L · CIK 0001799081 · SVP and General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,409

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019.

SEC source: 0001209191-20-043123 · doc4.xml · derivative · entry 3

BENZENO SHARON · CIK 0001780854 · Chief Business Development Off

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,750

Underlying: Common Stock · 417 shares

Expires 2027-04-25

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 16, 2020.

F2 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on April 19, 2018, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.

SEC source: 0001209191-20-043123 · doc4.xml · nonDerivative · entry 2

BENZENO SHARON · CIK 0001780854 · Chief Business Development Off

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 16, 2020.

SEC source: 0001209191-20-043123 · doc4.xml · nonDerivative · entry 1

BENZENO SHARON · CIK 0001780854 · Chief Business Development Off

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 417

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 16, 2020.

SEC source: 0000902664-20-002761 · ownership.xml · nonDerivative · entry 1

GOEL DAVID E. · CIK 0001548144 · Director · 10% owner · See Remarks

Matrix Capital Management Company, LP · CIK 0001410830 · Director · 10% owner · See Remarks

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnotes

Disclosed balance after: 13,115,090

F1 · ownership.nature: The securities reported herein are held by Matrix Capital Management Master Fund, LP (the "Matrix Fund"). Matrix Capital Management Company, LP (the "Investment Manager"), a Delaware limited partnership, is the investment advisor to the Matrix Fund. Mr. David E. Goel ("Mr. Goel", and together with the Investment Manager, the "Reporting Persons"), serves as the Managing General Partner of the Investment Manager.

F2 · ownership.nature: The filing of this statement shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein.

SEC source: 0001209191-20-043010 · doc4.xml · derivative · entry 9

ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 366,900

Underlying: Common Stock · 11,100 shares

Expires 2025-06-09

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019.

F7 · derivative.exercise_date: The option is fully vested and exercisable.

SEC source: 0001209191-20-043010 · doc4.xml · nonDerivative · entry 7

ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 679

F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019.

F6 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $40.05 to 40.54, inclusive.

SEC source: 0001209191-20-043010 · doc4.xml · nonDerivative · entry 6

ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,385

F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019.

F5 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $39.03 to 39.98, inclusive.

SEC source: 0001209191-20-043010 · doc4.xml · nonDerivative · entry 5

ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,579

F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019.

F4 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $38.40 to 38.82, inclusive.

SEC source: 0001209191-20-043010 · doc4.xml · nonDerivative · entry 4

ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,779

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019.

SEC source: 0001209191-20-043010 · doc4.xml · derivative · entry 8

ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 378,000

Underlying: Common Stock · 22,200 shares

Expires 2025-06-09

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019.

F7 · derivative.exercise_date: The option is fully vested and exercisable.

SEC source: 0001209191-20-043010 · doc4.xml · nonDerivative · entry 3

ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 679

F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019.

F3 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $39.80 to 40.23, inclusive.

SEC source: 0001209191-20-043010 · doc4.xml · nonDerivative · entry 2

ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,059

F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019.

F2 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $38.80 to 39.79, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

SEC source: 0001209191-20-043010 · doc4.xml · nonDerivative · entry 1

ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 22,879

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019.

SEC source: 0001209191-20-043012 · doc4.xml · derivative · entry 5

LO FRANCIS · CIK 0001780660 · Chief People Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 196,000

Underlying: Common Stock · 2,000 shares

Expires 2029-05-06

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 18, 2020.

F3 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on May 6, 2020, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.

SEC source: 0001209191-20-043012 · doc4.xml · nonDerivative · entry 3

LO FRANCIS · CIK 0001780660 · Chief People Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 18, 2020.

F2 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $43.06 to 44.04, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

SEC source: 0001209191-20-043012 · doc4.xml · nonDerivative · entry 2

LO FRANCIS · CIK 0001780660 · Chief People Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 500

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 18, 2020.

F2 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $43.06 to 44.04, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

SEC source: 0001209191-20-043012 · doc4.xml · nonDerivative · entry 1

LO FRANCIS · CIK 0001780660 · Chief People Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 18, 2020.

SEC source: 0001209191-20-043011 · doc4.xml · derivative · entry 4

HERSHBERG ROBERT · CIK 0001274139 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 69,000

Underlying: Common Stock · 2,000 shares

Expires 2023-02-04

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 13, 2020.

F4 · derivative.exercise_date: The option is fully vested and exercisable.

SEC source: 0001209191-20-043011 · doc4.xml · nonDerivative · entry 3

HERSHBERG ROBERT · CIK 0001274139 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 13, 2020.

F3 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $43.03 to 43.85, inclusive.

SEC source: 0001209191-20-043011 · doc4.xml · nonDerivative · entry 2

HERSHBERG ROBERT · CIK 0001274139 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 500

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 13, 2020.

F2 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $43.06 to $44.04, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

SEC source: 0001209191-20-043011 · doc4.xml · nonDerivative · entry 1

HERSHBERG ROBERT · CIK 0001274139 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 13, 2020.

SEC source: 0001209191-20-042222 · doc4.xml · derivative · entry 3

RUBINSTEIN JULIE · CIK 0001780664 · President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 94,725

Underlying: Common Stock · 15,275 shares

Expires 2024-03-13

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 15, 2019.

F2 · derivative.exercise_date: The option is fully vested and exercisable.

SEC source: 0001209191-20-042222 · doc4.xml · nonDerivative · entry 2

RUBINSTEIN JULIE · CIK 0001780664 · President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 15, 2019.

SEC source: 0001209191-20-042222 · doc4.xml · nonDerivative · entry 1

RUBINSTEIN JULIE · CIK 0001780664 · President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,275

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 15, 2019.

SEC source: 0001209191-20-042221 · doc4.xml · derivative · entry 6

HILL NANCY LOUISE · CIK 0001780790 · EVP, Operations & Program Mana

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 100,600

Underlying: Common Stock · 17,400 shares

Expires 2023-11-03

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 21, 2020.

F4 · derivative.exercise_date: The option is fully vested and exercisable.

SEC source: 0001209191-20-042221 · doc4.xml · nonDerivative · entry 2

HILL NANCY LOUISE · CIK 0001780790 · EVP, Operations & Program Mana

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,000

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 21, 2020.

F2 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $49.00 to 49.01, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

SEC source: 0001209191-20-042221 · doc4.xml · nonDerivative · entry 1

HILL NANCY LOUISE · CIK 0001780790 · EVP, Operations & Program Mana

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 27,400

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 21, 2020.